VP1-2023: Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study

S.Y. Rha; L.S. Wyrwicz; P.E.Y. Weber; Y. Bai; M.H. Ryu; J. Lee; F. Rivera; G.V. Alves; M. Garrido; K-K. Shiu; M. González Fernández; J. Li; M. Lowery; T. Cil; F.J.S.M. Cruz; S. Qin; L. Yin; S. Bordia; P. Bhagia; D-Y. Oh

doi:10.1016/j.annonc.2023.01.006

YUHSpace

BROWSE

0 75

Cited 0 times in

VP1-2023: Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study

Authors: S.Y. Rha ; L.S. Wyrwicz ; P.E.Y. Weber ; Y. Bai ; M.H. Ryu ; J. Lee ; F. Rivera ; G.V. Alves ; M. Garrido ; K-K. Shiu ; M. González Fernández ; J. Li ; M. Lowery ; T. Cil ; F.J.S.M. Cruz ; S. Qin ; L. Yin ; S. Bordia ; P. Bhagia ; D-Y. Oh